NFKB1 and lymphoma: TRIM21/Ro52 deficiency may be relevant to the increased risk of lymphoma because of NF‐κB pathway activation, and maintaining TRIM21 expression is also associated with a preferable clinical outcome in patients with lymphoma [12, 29].